Bortezomib Treatment Modulates Autophagy in Multiple Myeloma.
Giuseppe Di LerniaPatrizia LeoneAntonio Giovanni SolimandoAlessio BuonavogliaIlaria SaltarellaRoberto RiaPaolo DitonnoNicola SilvestrisLucilla CrudeleAngelo VaccaVito RacanelliPublished in: Journal of clinical medicine (2020)
Our results suggest that treatment with bortezomib and HCQ should be associated with an anti-angiogenic drug to prevent the pro-angiogenic effect of bortezomib, the proliferation of a small residual tumor PC clone, and thus the relapse.